6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
Just now	Lantronix Debuts NDAA-Compliant Open‑Q 8550CS µSOM for Next‑Generation Autonomous Drones at XPONENTIAL 2026
Just now	Kirby Corporation Announces First Quarter 2026 Results
Just now	GigaCloud Technology Inc to Announce First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Just now	T. ROWE PRICE GROUP REPORTS FIRST QUARTER 2026 RESULTS
Just now	Balchem Corporation Reports First Quarter 2026 Financial Results

About

Sab Biotherapeutics Inc (NASDAQ:SABS) — investor relations, events, news, and company updates on 6ix.

Latest News

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Financials

Revenue

$114.7 K

Market Cap

$272.67 M

EPS

-0.79

Community Chat

Ask AI